Designer Baby Companies Are in Turmoil

Manhattan Genomics and Bootstrap Bio, two startups focused on gene-edited babies, have shut down after launch.

One cited a lack of funding, while the other was derailed by a cofounder dispute.

Both companies had planned to pursue germline embryo editing to prevent disease in future children.

The closures highlight the scientific, legal, and ethical barriers still facing embryo gene-editing ventures.